Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BGIICC 2018 /
Different treatment strategies for BRCA positive breast cancer

18th - 19th Jan 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.01.18
Views: 3489

Prof Banu Arun - MD Anderson Center, Houston, USA

Prof Arun speaks with ecancer at the 10th BGICC in Cairo about the changing field of treatments for patients with BRCA breast cancer.

She notes recent drug approvals, including olaparib, and the outcomes of the Embraca trial of talazoparib.

For all of our coverage of the San Antonio Breast Cancer Symposium 2017, click here.

Prof Arun also spoke with ecancer about adjuvant and neoadjuvant strategies for triple negative breast cancer, here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation